BridgeBio Pharma, Inc. (BBIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
BBIO POWR Grades
- BBIO scores best on the Value dimension, with a Value rank ahead of 59.05% of US stocks.
- BBIO's strongest trending metric is Quality; it's been moving up over the last 178 days.
- BBIO's current lowest rank is in the Stability metric (where it is better than 4.32% of US stocks).
BBIO Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for BBIO is -0.08 -- better than just 6.65% of US stocks.
- With a price/sales ratio of 15.56, BRIDGEBIO PHARMA INC has a higher such ratio than 92.81% of stocks in our set.
- BBIO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 5.47% of US stocks.
- If you're looking for stocks that are quantitatively similar to BRIDGEBIO PHARMA INC, a group of peers worth examining would be STRO, EDIT, DTIL, RARE, and CYCN.
- Visit BBIO's SEC page to see the company's official filings. To visit the company's web site, go to bridgebio.com.
BBIO Valuation Summary
- BBIO's price/sales ratio is 16; this is 220% higher than that of the median Healthcare stock.
- BBIO's price/earnings ratio has moved up 19.1 over the prior 42 months.
Below are key valuation metrics over time for BBIO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BBIO | 2022-12-02 | 16.0 | -1.2 | -2.9 | -6.4 |
| BBIO | 2022-12-01 | 15.6 | -1.2 | -2.8 | -6.3 |
| BBIO | 2022-11-30 | 15.8 | -1.2 | -2.9 | -6.3 |
| BBIO | 2022-11-29 | 14.7 | -1.1 | -2.7 | -6.1 |
| BBIO | 2022-11-28 | 13.7 | -1.1 | -2.5 | -5.9 |
| BBIO | 2022-11-25 | 14.5 | -1.1 | -2.6 | -6.1 |
BBIO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BBIO has a Quality Grade of D, ranking ahead of 17.97% of graded US stocks.
- BBIO's asset turnover comes in at 0.068 -- ranking 297th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows BBIO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.068 | 0.998 | -0.332 |
| 2021-03-31 | 0.010 | 1.000 | -0.451 |
| 2020-12-31 | 0.010 | 1.000 | -0.555 |
| 2020-09-30 | 0.026 | 1.000 | -0.593 |
| 2020-06-30 | 0.051 | 0.938 | -0.669 |
| 2020-03-31 | 0.063 | 0.938 | -0.909 |
BBIO Price Target
For more insight on analysts targets of BBIO, see our BBIO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $80.40 | Average Broker Recommendation | 1.28 (Strong Buy) |
BBIO Stock Price Chart Interactive Chart >
BBIO Price/Volume Stats
| Current price | $9.47 | 52-week high | $18.13 |
| Prev. close | $9.23 | 52-week low | $4.98 |
| Day low | $8.86 | Volume | 1,313,700 |
| Day high | $9.55 | Avg. volume | 2,239,432 |
| 50-day MA | $10.01 | Dividend yield | N/A |
| 200-day MA | $9.48 | Market Cap | 1.42B |
BridgeBio Pharma, Inc. (BBIO) Company Bio
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Latest BBIO News From Around the Web
Below are the latest news stories about BRIDGEBIO PHARMA INC that investors may wish to consider to help them evaluate BBIO as an investment opportunity.
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Guardant Health (GH) and BridgeBio Pharma (BBIO)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intuitive Surgical (ISRG – Research Report), Guardant Health (GH – Research Report) and BridgeBio Pharma (BBIO – Research Report) with bullish sentiments. Intuitive Surgical (ISRG) J.P. Morgan analyst Robbie Marcus maintained a Buy rating on Intuitive Surgical yesterday and set a price target of $280.00. The company's shares closed last Thursday at $260.77. According to TipRanks. |
BridgeBio Pharma to Participate in November Investor EventsPALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences: Jefferies Health Care Conference, London, UK: November 15th at 9:40 am ETEvercore ISI HealthCONx Conference, Virtual: November 30th at 10:05 am ET To access the live webcast |
BridgeBio Pharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagBridgeBio Pharma ( NASDAQ:BBIO ) Third Quarter 2022 Results Key Financial Results Revenue: US$338.0k (down 86% from 3Q... |
Mizuho Securities Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on BridgeBio Pharma (BBIO - Research Report), with a price target of $23.00. The company's shares opened today at $10.02.Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Biogen, and Coherus Biosciences. According to TipRanks, Syed has an average return of -16.2% and a 33.82% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BridgeBio Pharma with a $23.00 average price target, which is a 129.54% upside from current levels. |
BridgeBio Pharma (BBIO) Reports Q3 Loss, Misses Revenue EstimatesBridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 8.82% and 94.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
BBIO Price Returns
| 1-mo | -3.76% |
| 3-mo | -3.47% |
| 6-mo | 21.25% |
| 1-year | -26.44% |
| 3-year | -13.96% |
| 5-year | N/A |
| YTD | -43.23% |
| 2021 | -29.63% |
| 2020 | 102.88% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...